Biopharmaceutical Executive with 20+ years of progressive leadership experience across a broad spectrum of functions with a strong track record of building life sciences companies through capital investment, establishing top-tier leadership teams and launching novel technologies in both oncology and rare diseases. A globally renowned expert in Cell/Gene therapies and Radiopharmaceuticals. Leads sizeable multi-disciplinary organizations in operations, pharmaceutical new product development, technical transfer, launches and ventures involving the building and set-up of new facilities and organizations. Launched 5 FDA-approved treatments - AMTAGVI™, Ultra-Technekow™ V4 (Technetium Tc 99m) Generator, Sestamibi™, Proquad Vaccine™ and Detectnet™. Led the development and launch of Xenon-133 Gas, Germanium-68, LEU Molybdenum-99 and I-123 medical isotopes. Recognized as a motivational mentor with an eye for key talent in building high performance teams committed to excellence. Known for consistently exceeding results, implementing change programs and transforming under-performing areas. Creates strong relationships across functional and organizational boundaries.
Listed skills include Fda, Gmp, Manufacturing, Validation, and 46 others.